# US 7,410,776 B2 · Polypeptides, their production and use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,410,776 B2
- Document ID: US7410776B2
- Status: Granted
- Kind: B2
- Application number: 10/184,722
- Filed: 2002-06-27
- Published: 2003-05-15
- Granted: 2008-08-12
- Earliest claimed: 1997-12-24
- Assignees: Takeda Pharmaceutical Company Limited
- Inventors: Shuji Hinuma; Kazuhiko Tatemoto; Masaki Hosoya; Yugo Habata; Ryo Fujii; Chieko Kitada
- Web page: https://patentgrep.com/patent/US7410776B2

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/4702: {Regulators; Modulating activity}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention relates to a novel polypeptide involving in the modulation of central nervous system function, circulatory function, immune function, gastrointestinal function, metabolic function, reproductive function, etc., it can be used as a drug for treating or preventing a variety of diseases, e.g. HIV infection or AIDS (acquired immune deficiency syndrome) or the like.

## Claims

### Claim 1

An isolated DNA comprising a nucleotide sequence coding for a ligand polypeptide capable of binding to a receptor protein, wherein the receptor protein comprises the amino acid sequence of SEQ ID NO: 3, and wherein the ligand polypeptide comprises the amino acid sequence of SEQ ID NO: 40.

### Claim 2 (depends on 1)

A recombinant vector which comprises the DNA as claimed in claim 1.

### Claim 3 (depends on 1, 2)

A transformant carrying the DNA as claimed in claim 1 or the recombinant vector as claimed in claim 2.

### Claim 4 (depends on 3)

A method for producing a polypeptide, a precursor polypeptide thereof or a salt thereof which comprises cultivating the transformant as claimed in claim 3.